Subgroups
Bayer HealthCare
-
Thursday - August 21, 2008
Bayer and Onyx continue clinical investigation of sorafenib:
New Trial to Evaluate Nexavar® as Adjuvant Therapy in Liver Cancer
Enrollment initiated in international phase III study
-
Tuesday - August 19, 2008
Bayer HealthCare and Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-related Macular Degeneration
Study patients, on average, received only two additional doses following a 12-week fixed dosing period
-
Tuesday - August 19, 2008
Bayer Schering Pharma to support USAID with contraceptives for family planning programs
Access to family planning for more than 8 million women in developing countries / 110 million cycles of oral contraceptives to be provided each year
-
Thursday - August 7, 2008
Bayer Schering Pharma strengthens its oncology R&D portfolio
Bayer acquires Preclinical Anti-cancer Program from Nycomed
Company assuming full development and commercialization rights
-
Wednesday - July 30, 2008
Interim report for the second quarter of 2008
Bayer continues its success
Sales up 3.6 percent to EUR 8,511 million / EBITDA before special items increases by 5.0 percent to EUR 1,896 million / EBIT before special items improves by 5.3 percent to EUR 1,248 million / Full-year guidance for CropScience raised again / Group earnings forecast confirmed
-
Wednesday - July 30, 2008
Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:
Bayer’s Novel Anticoagulant Rivaroxaban Submitted for Approval in the U.S.
Rivaroxaban is first oral anticoagulant to achieve superior efficacy over the twice-daily injection of enoxaparin while maintaining low rates of major bleeding / No evidence of safety issues attributable to rivaroxaban after long-term exposure
-
Monday - July 28, 2008
Another milestone for cancer drug from Bayer and Onyx:
Nexavar Approved for Treatment of Liver Cancer in China
Nexavar is First Approved Systemic Therapy to Treat the Disease
-
Friday - July 25, 2008
Study Confirms that Levitra® on demand is Effective in Patients with ED after Nerve-sparing Prostatectomy
-
Friday - July 25, 2008
Venous Blood Clot Prevention after Elective Hip or Knee Replacement Surgery:
Bayer’s Novel Anticoagulant Rivaroxaban Recommended for Approval in the EU
Final approval from the European Commission expected within the next few months
-
Friday - July 25, 2008
Andreas Fibig named new Chairman of the Board of Management of Bayer Schering Pharma
Dr. Bernd Metzner to become new Board member of Bayer’s pharmaceuticals subsidiary / Arthur Higgins and Werner Baumann to refocus on their leadership roles in the Bayer HealthCare subgroup following the successful integration of Bayer Schering Pharma
-
Friday - July 25, 2008
Bayer welcomes the proposed EMEA labeling changes for moxifloxacin which are consistent with existing guidelines for appropriate use of fluoroquinolone antibiotics
-
Thursday - July 24, 2008
Publication in New England Journal of Medicine:
Nexavar Study Demonstrates Significant Improvement in Overall Survival in Patients with Liver Cancer
Nexavar is First Approved Systemic Therapy to Treat the Disease
-
Thursday - July 10, 2008
Overcoming boundaries:
Geri Winkler becomes the first diabetic to conquer the Seven Summits
Adventurer reaches the peak of Mount McKinley (Denali) in Alaska
-
Tuesday - July 8, 2008
First organ-specific diagnostic agent approved in the U.S. in more than a decade:
Primovist® approved in the U.S. for the Detection and Characterization of Liver Lesions
-
Tuesday - July 8, 2008
Bayer Animal Health at the XXVth World Buiatrics Congress in Budapest:
Pharmaceuticals for the global cattle market gain further significance
Calf coccidiosis in the spotlight
-
Tuesday - July 8, 2008
XXV. World Buiatrics Congress in Budapest
Coccidiosis in cattle – an underestimated problem
-
Tuesday - July 8, 2008
Bayer Animal Health at the XXVth World Buiatrics Congress in Budapest
-
Tuesday - July 8, 2008
Bayer Animal Health at the XXVth World Buiatrics Congress in Budapest
Photos
-
Wednesday - July 2, 2008
Bayer HealthCare Completes Acquisition of Western OTC Cough and Cold Business of Topsun Science and Technology
Significantly Strengthens Consumer Care Division’s Business in High Growth Chinese OTC Market
-
Wednesday - July 2, 2008
Bayer Expands Hemophilia Portfolio
Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen
Phase 1 clinical testing expected to commence in third quarter of 2008 / Transaction includes license to Maxygen’s novel biotechnology research platform
Search
Links
Publications
Stockholder's Newsletter
Annual Report 2007
Sustainable Development Report 2007
research – The Bayer Scientific Magazine
Publications Overview
Newsletter
Events
Download Center - Selection